This 2018 review examines the rising prevalence of pediatric allergic diseases in China, including asthma, allergic rhinitis, and atopic eczema, correlating with rapid urbanization and lifestyle changes. Despite the increasing disease burden, pediatric allergy as a subspecialty remains underdeveloped due to the lack of formal training programs and certification. Efforts
This 2018 review article in Nutrients by Avery and Hoffmann delves into the pivotal role of selenium and its incorporation into selenoproteins in modulating immune responses. Selenium, an essential trace element, is integral to the function of 25 known human selenoproteins, many of which are involved in antioxidant defense and
This 2023 review article, published in Mediterranean Journal of Rheumatology, explores the potential applications of low-dose naltrexone (LDN) in various rheumatological conditions. The authors discuss LDN’s immunomodulatory properties, particularly its ability to modulate the opioid growth factor (OGF)–OGF receptor (OGFr) axis, which may lead to reduced inflammation and pain. The
This 2020 study, published in the Journal of Biological Chemistry, investigates the effects of low-dose naltrexone (LDN) on inflammation and insulin resistance induced by hyperinsulinemia. Using in vitro models, the researchers demonstrated that LDN treatment reduced pro-inflammatory cytokine production and improved insulin signaling pathways. The findings suggest that LDN may
This 2023 study, published in International Immunopharmacology, investigates the potential of low-dose naltrexone (LDN) in treating post-acute sequelae of COVID-19 (PASC), commonly known as long COVID. The researchers explored LDN’s immunomodulatory effects, particularly its ability to reduce neuroinflammation and modulate immune responses, which are believed to contribute to long COVID
This 2022 review article, published in Expert Review of Anticancer Therapy by Wai M. Liu and Angus G. Dalgleish, explores the potential of low-dose naltrexone (LDN) as an adjunctive treatment in oncology. The authors discuss how LDN, administered at doses significantly lower than those used for addiction treatment, may exert
This 2019 study, published in Frontiers in Immunology, investigates the effect of low-dose naltrexone (LDN) on the function of Transient Receptor Potential Melastatin 3 (TRPM3) ion channels in natural killer (NK) cells from patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The researchers found that TRPM3 channel activity was significantly impaired
This 2013 study by Diken et al. explored the synergistic potential of combining mTOR inhibition with RNA-based cancer vaccination. Utilizing a B16 melanoma model expressing ovalbumin in C57BL/6 mice, researchers administered intranodal injections of in vitro transcribed RNA encoding the tumor antigen, followed by rapamycin treatment during the effector-to-memory transition
This 2021 review article, published in Frontiers in Immunology, explores the potential therapeutic role of low-dose naltrexone (LDN) in treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The authors discuss how LDN, typically administered at doses of 1.5 to 4.5 mg daily, may alleviate ME/CFS symptoms by modulating the Transient Receptor Potential
This 2013 study by Boor et al. examined how rapamycin, an mTOR inhibitor, modulates the functions of human plasmacytoid dendritic cells (pDCs), which are pivotal in both innate and adaptive immunity. At clinically relevant concentrations, rapamycin significantly suppressed Toll-like receptor 7 (TLR7)-induced interferon-alpha (IFN-α) production by 64% and modestly reduced
